Share on LinkedInShare on LinkedIn

ARTICLE · 18 AUGUST 2015

Generic Competitor's Regulatory Issues Prompt Stay Of Lialda® Patent Litigation

As set forth in the decision, Mylan's failure to respond to a deficiency letter received from FDA in May 2014 "raise[d] serious questions in the Court's mind as to the viability of Mylan's ANDA product as currently formulated."

United StatesIntellectual Property

In a first-of-its-kind public decision, Frommer Lawrence & Haug LLP obtained a stay and administrative closure of a Hatch-Waxman patent case on behalf of its client Shire Pharmaceuticals, because of the generic drug maker Mylan Pharmaceuticals' problems with their application in the FDA. Judge Charlene Honeywell, of the U.S. Middle District of Florida stated that the uncertainty surrounding the status of Mylan's proposed generic product warranted her action.

As set forth in the decision, Mylan's failure to respond to a deficiency letter received from FDA in May 2014 "raise[d] serious questions in the Court's mind as to the viability of Mylan's ANDA product as currently formulated." And Mylan's June 2015 request for a year-long extension to respond to FDA – made three months prior to trial – "further reinforce[d] that there is a significant possibility that Mylan's product will have to be reformulated and/or its ANDA materially amended."

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from